MII IG Kerndatensatz-Modul Molekulares Tumorboard
2027.0.0-ballot.1 - Germany

This page is part of the MII Implementation Guide Molecular Tumor Board (v2027.0.0-ballot.1: Release) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version in its permanent home (it will always be available at this URL). For a full list of available versions, see the Directory of published versions

Example Claim: 10.03.2023 Krankenkassenantrag gestellt Mirvetuximab soravtansine

English

Profile: MII PR MTB Antrag Kostenuebernahme version: 2027.0.0-ballot.1

status: Active

type: institutional

use: Claim

patient: Kim Musterperson (no stated gender), DoB: 1956-03-14

created: 2023-03-10

provider: Organization Example General Hospital

priority: Normal

Relateds

-Relationship
*initial-claim

prescription: MedicationRequest: extension = 1,Predictive value of the biomarker or clinical effectiveness of the corresponding drug in a molecularly stratified cohort was demonstrated in a prospective study or a meta-analysis in the same tumor type.,http://doi.org#10.1200/JCO.2022.40.16_suppl.5512,http://www.ncbi.nlm.nih.gov/pubmed#38055253; status = completed; intent = proposal; medication[x] = MIRVETUXIMAB SORAVTANSINE; authoredOn = 2023-03-28

CareTeams

-SequenceProviderResponsible
*1Organization Example Health Insurance Co.true

Insurances

-SequenceFocalCoverageClaimResponse
*1trueCoverage: status = active; type = extended healthcare; period = 2023-01-01 --> 2025-12-31ClaimResponse: status = active; type = institutional; use = claim; created = 2023-05-01; outcome = complete